Immunomodulators (IMDs) Today

Immunomodulators (IMDs) Today

/in , /by

A panel of experts discuss the bedrock therapy in multiple myeloma immunomodulators (IMDs).

The panel includes:

  • Jenny Ahlstrom – Founder and Chief Executive Officer, Healthtree Foundation
  • Diane Moran – Business Relationship Management, International Myeloma Foundation
  • Pamela Price – Deputy Director, Balm in Gilead
  • Christopher Peña – Director, Educational Programs, Multiple Myeloma Research Foundation

Brought to you by the Multiple Myeloma Collective, Sponsored by Bristol Myers Squibb

You might also like
How a Second Opinion Saved a Myeloma Patient's LifeHow a Second Opinion Saved a Myeloma Patient’s Life
Acute Myeloid Leukemia Care | Who Are the Essential Team MembersAcute Myeloid Leukemia Care | Who Are the Essential Team Members?
Advances in Managing CAR T-Cell Therapy Side EffectsAdvances in Managing CAR T-Cell Therapy Side Effects
Myeloma Take Action ChecklistMyeloma Take Action Checklist
Is MGUS More Prevalent in BIPOC Communities?Is MGUS More Prevalent in BIPOC Communities?
Why Is a Care Partner Essential for Patients Undergoing CAR T-Cell Therapy?Why Is a Care Partner Essential for Patients Undergoing CAR T-Cell Therapy?